The IPO pricing at the high end of the range with an upsized offering indicates strong demand. The concurrent Sanofi investment at the same price validates the platform. Monitor first-day trading volume and price action for post-IPO float dynamics. Key catalysts to watch: STX-1150 clinical data readouts and any further partnership announcements from Eli Lilly or Sanofi.
Price Chart
Executive Summary
Scribe Therapeutics (SCTX) priced its upsized IPO of 8,580,000 shares at $15.00/share, raising $128.7M in gross proceeds, with shares trading on Nasdaq starting July 24, 2026. Concurrently, a $7.5M private placement to Sanofi was announced, and multiple major insiders (Eli Lilly, OrbiMed, a16z, Jennifer Doudna, Carl Gordon, Svetlana Lucas) filed initial Form 3 ownership statements reflecting pre-IPO holdings that will convert to common stock upon IPO close. The IPO represents the company's public market debut and provides a significant capital infusion for its CRISPR-based cardiometabolic pipeline, while the Sanofi placement signals strategic pharma interest beyond existing collaborations.
Key Facts
- IPO of 8,580,000 shares at $15.00/share raised $128.7M in gross proceeds
- Concurrent private placement of 500,000 shares at $15.00/share to Sanofi for $7.5M
- Shares begin trading on Nasdaq on July 24, 2026 under ticker SCTX
- Eli Lilly reported beneficial ownership of 1,054,828 shares of common stock
- OrbiMed Advisors/OrbiMed Capital GP VIII reported 348,825 shares of common stock (convertible from Series B Preferred)
- a16z (AH Bio Fund II/III) reported 2,051,742 shares (Series A Preferred) and 697,650 shares (Series B Preferred) convertible to common
- Jennifer Doudna reported 591,036 shares of common stock and 12,511 shares from Series A-1 Preferred
- Carl L. Gordon (OrbiMed) reported 348,825 shares of common stock (indirect via OrbiMed)
- Svetlana Lucas (Chief Business Officer) reported 30,695 shares of common stock and options for 92,332 shares
- Underwriters have a 30-day option for an additional 1,287,000 shares
Financial Impact
Gross IPO proceeds of $128.7M plus $7.5M from Sanofi private placement = $136.2M total capital raised
Risk Factors
- Post-IPO lockup expirations could create selling pressure from pre-IPO holders
- Clinical-stage biotech with no approved products - pipeline execution risk
- Dilution from full exercise of underwriter option (additional 1.287M shares)
- Competition in CRISPR-based cardiometabolic space
- Pre-revenue company with ongoing R&D expenses
Investment Themes
Documents Analyzed
This report is based on 41 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (SCTX) — Batch item 1 | 0001193125-26-314787 |
| Document: 0001193125-26-314787-index.html | 0000947871-26-000715 |
| Document: 0001193125-26-314787.txt | 0001231919-26-000795 |
| 3 Filing (SCTX) — Batch item 4 | 0000947871-26-000715 |
| Document: 0000947871-26-000715-index.html | 0001282930-26-000002 |
| Document: 0000947871-26-000715.txt | 0001781292-26-000005 |
| 3 Filing (SCTX) — Batch item 7 | 0001231919-26-000795 |
| Exhibit: ex24-07242026_010750.htm | 0000947871-26-000715 |
| Document: 0001231919-26-000795-index-headers.html | 0001231919-26-000795 |
| Document: 0001231919-26-000795-index.html | 0001739090-26-000008 |
| Document: 0001231919-26-000795.txt | 0001282930-26-000002 |
| 3 Filing (SCTX) — Batch item 12 | 0001739090-26-000008 |
| Document: 0001739090-26-000008-index.html | 0001193125-26-314787 |
| Document: 0001739090-26-000008.txt | 0001193125-26-314787 |
| 3 Filing (SCTX) — Batch item 15 | 0001282930-26-000002 |
| Document: 0001282930-26-000002-index-headers.html | 0001193125-26-314787 |
| Document: 0001282930-26-000002-index.html | 0001193125-26-314787 |
| Document: 0001282930-26-000002.txt | 0001193125-26-314787 |
| 3 Filing (SCTX) — Batch item 19 | 0001781292-26-000005 |
| Document: 0001781292-26-000005-index-headers.html | 0001193125-26-314787 |
| Document: 0001781292-26-000005-index.html | 0001193125-26-314787 |
| Document: 0001781292-26-000005.txt | 0001193125-26-314787 |
| 3 Filing (SCTX) — Batch item 23 | 0001193125-26-314787 |
| Document: 0001193125-26-314787-index.html | 0001193125-26-314787 |
| Document: 0001193125-26-314787.txt | 0001193125-26-314787 |
| 3 Filing (SCTX) — Batch item 26 | 0000947871-26-000715 |
| Document: 0000947871-26-000715-index.html | 0001193125-26-314787 |
| Document: 0000947871-26-000715.txt | 0001193125-26-314787 |
| 3 Filing (SCTX) — Batch item 29 | 0001231919-26-000795 |
| Exhibit: ex24-07242026_010750.htm | 0001193125-26-314787 |
| Document: 0001231919-26-000795-index-headers.html | 0001193125-26-314787 |
| Document: 0001231919-26-000795-index.html | 0001193125-26-314787 |
| Document: 0001231919-26-000795.txt | 0001193125-26-314787 |
| 3 Filing (SCTX) — Batch item 34 | 0001739090-26-000008 |
| Document: 0001739090-26-000008-index.html | 0001193125-26-314787 |
| Document: 0001739090-26-000008.txt | 0001193125-26-314787 |
| 3 Filing (SCTX) — Batch item 37 | 0001282930-26-000002 |
| Document: 0001282930-26-000002-index-headers.html | 0001193125-26-314787 |
| Document: 0001282930-26-000002-index.html | 0001193125-26-314787 |
| Document: 0001282930-26-000002.txt | 0001193125-26-314787 |
| PRESS-RELEASE Data (Synthetic) | 0001193125-26-314787 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 7w ago | 8-K | $30.81 $16.79 | ▼ −45.50% | ▼ −44.32% | $15.60 (−49.37%) |
Sep 2, 2026 7w ago | Press Release | $30.81 $16.79 | ▼ −45.50% | ▼ −44.32% | $15.60 (−49.37%) |
Jul 29, 2026 12w ago | Insider Cluster | $20.40 $28.84 | ▲ +41.37% | ▲ +37.41% | $15.60 (−23.53%) |
Jul 29, 2026 12w ago | Insider Cluster | $20.40 $28.84 | ▲ +41.37% | ▲ +37.41% | $15.60 (−23.53%) |
Jul 28, 2026 12w ago | Insider Cluster | $18.36 $31.70 | ▲ +72.66% | ▲ +67.64% | $15.60 (−15.03%) |
Jul 24, 2026 13w ago | 424B4 | $18.97 $37.25 | ▲ +96.36% | ▲ +93.06% | $15.60 (−17.76%) |
Jul 24, 2026 13w ago | EFFECT | $21.65 $34.13 | ▲ +57.64% | ▲ +54.02% | $15.60 (−27.94%) |
Jul 23, 2026 13w ago | 3 / PRESS-RELEASE | $21.65 $34.13 | ▲ +57.64% | ▲ +54.02% | $15.60 (−27.94%) |
Jul 20, 2026 14w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers